News & Events

- 4 June 2013 London - UK

Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063, for the Treatment of Hearing Loss and Tinnitus and Tops Up Series A Financing with Further 5.5 million Investment

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the start of a Phase I clinical study of the novel, first-in-class…
Read More

adm1nNo CommentsHearing Disorders, News

‘The Abandoned Illness’ a report by the Schizophrenia Commission

The Schizophrenia Commission was established in November 2011 by Rethink Mental Illness. The independent Commission was made up of 14 experts who have worked together to review how outcomes for…
Read More

adm1nNews, Schizophrenia

About

Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.

Science

Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.

Pipeline

Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.

Tweets

AutifonyLtd @AutifonyLtd
Autifony Therapeutic  @AutifonyLtd
Autifony reports positive results in Phase Ib trial with AUT00206, its novel Kv3 ion channel modulator, please take… https://t.co/A1hedx6tYy 
Apr 15 reply retweet favorite 6 days ago
Autifony Therapeutic  @AutifonyLtd
Autifony Therapeutics achieves first milestone in agreement with Boehringer Ingelheim for a novel therapeutic appro… https://t.co/xOlDJ1kTe9 
Jan 18 reply retweet favorite 3 months ago
Autifony Therapeutic  @AutifonyLtd
Autifony is currently recruiting a Junior Medicinal Chemist, the position will be based in our lab in Stevenage, fo… https://t.co/PkP9TCxUcq 
Dec 04 reply retweet favorite 5 months ago

Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image